Australia · Delayed Price · Currency is AUD Algorae Pharmaceuticals Company Description
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.
The company’s product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer’s disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson’s disease.
It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development.
The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023.
Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
| CEO | David Hainsworth |
Contact Details
Address: Rialto South Tower Melbourne, VIC 3000 Australia | |
| Phone | 61 2 9698 5414 |
| Website | algoraepharma.com |
Stock Details
| Ticker Symbol | 1AI |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000LCT6 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Richard Hainsworth | Chief Executive Officer and Executive Chairman |
| Vishal Shah | Chief Commercial Officer |
| Dr. James A. Mckenna | Chief Scientific Officer |
| Dr. Carolyn M. Sue A.M., B.S., Ph.D. | Member of Medical Advisory Board and Chief Medical Officer of NTCELL |
| Jennifer Voon | Company Secretary |